Generative Humanization for Therapeutic Antibodies
Antibody therapies have been employed to address some of today's most challenging diseases, but must meet many criteria during drug development before reaching a patient. Humanization is a sequence optimization strategy that addresses one critical risk called immunogenicity - a patient's immune response to the drug - by making an antibody more "human-like" in the absence of a predictive lab-based test for immunogenicity. However, existing humanization strategies generally yield very few humanized candidates, which may have degraded biophysical properties or decreased drug efficacy. Here, we re-frame humanization as a conditional generative modeling task, where humanizing mutations are sampled from a language model trained on human antibody data. We describe a sampling process that incorporates models of therapeutic attributes, such as antigen binding affinity, to obtain candidate sequences that have both reduced immunogenicity risk and maintained or improved therapeutic properties, allowing this algorithm to be readily embedded into an iterative antibody optimization campaign. We demonstrate in silico and in lab validation that in real therapeutic programs our generative humanization method produces diverse sets of antibodies that are both (1) highly-human and (2) have favorable therapeutic properties, such as improved binding to target antigens.
Code (0)
등록된 구현이 없습니다.
Tasks
Language ModelingLanguage ModellingSimilar Papers 제목 키워드 기반
Energy-based generative models for monoclonal antibodies
Since the approval of the first antibody drug in 1986, a total of 162 antibodies have been approved for a wide range of therapeutic areas, including cancer, autoimmune, infectious, or cardiovascular diseases. Despite adv…
Drug DiscoveryBayesian Optimization of Antibodies Informed by a Generative Model of Evolving Sequences
To build effective therapeutics, biologists iteratively mutate antibody sequences to improve binding and stability. Proposed mutations can be informed by previous measurements or by learning from large antibody databases…
Bayesian OptimizationLanguage ModelingLanguage ModellingLarge Language ModelIntegrating computational detection and experimental validation for rapid GFRAL-specific antibody discovery
The identification and validation of therapeutic antibodies is critical for developing effective treatments for many diseases. We present a computational approach for identifying antibodies targeting GFRAL-specific recep…
AntiBARTy Diffusion for Property Guided Antibody Design
Over the past decade, antibodies have steadily grown in therapeutic importance thanks to their high specificity and low risk of adverse effects compared to other drug modalities. While traditional antibody discovery is p…
DiversityLanguage ModelingLanguage ModellingSpecificityGuided Generation for Developable Antibodies
Therapeutic antibodies require not only high-affinity target engagement, but also favorable manufacturability, stability, and safety profiles for clinical effectiveness. These properties are collectively called `developa…